Noninvasive fetal RhD status determination in early pregnancy

Fetal Diagnosis and Therapy

Volumn 35, Issue 1, 2014, Pages 7-12

  Manzanares, Sebastian ^a   Entrala, Carmen ^b   Sánchez Gila, Mar ^a   Fernández Rosado, Francisco ^b   Cobo, Davinia ^a   Martinez, Esther ^b   Molina, Luis ^b   Reche, Rosa ^a   Pineda, Alicia ^a   Gallo, José Luis ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b Lorgen GP ^*  (Spain)

Author keywords

Cell free fetal DNA; Early pregnancy; Fetal RhD genotyping; Real time PCR prenatal diagnosis

Indexed keywords

RHESUS D ANTIBODY;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EXON; FALSE NEGATIVE RESULT; FEMALE; FETAL WELL BEING; FETUS FUNCTION TEST; FIRST TRIMESTER PREGNANCY; GENOTYPE; GESTATIONAL AGE; HUMAN; IMMUNOPROPHYLAXIS; MAJOR CLINICAL STUDY; MATERNAL PLASMA; MIDDLE AGED; NEWBORN; NON INVASIVE PROCEDURE; PHENOTYPE; PREDICTIVE VALUE; PREGNANT WOMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN DETERMINATION; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; UMBILICAL CORD BLOOD; YOUNG ADULT; ANTIBODY DETECTION; CELL FREE SYSTEM; DNA EXTRACTION; FALSE POSITIVE RESULT; FEASIBILITY STUDY; FETUS; MATERNAL BLOOD; QUANTITATIVE ANALYSIS;

FEMALE; GENOTYPING TECHNIQUES; HUMANS; MATERNAL AGE; MATERNAL SERUM SCREENING TESTS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY TRIMESTER, FIRST; RH-HR BLOOD-GROUP SYSTEM; SENSITIVITY AND SPECIFICITY;

EID: 84896718909     PISSN: 10153837     EISSN: 14219964     Source Type: Journal    
DOI: 10.1159/000356078     Document Type: Article

References (33)

1. Bowman JM: RhD hemolytic disease of the newborn. N Engl J Med 1998; 339: 1775-1777.
2. Eder A: Update on HDFN: new information on long-standing controversies. Immunohematology 2006; 22: 188-195.
3. Urbaniak S, Greiss S: RhD haemolytic disease of the fetus and the newborn. Blood Rev 2000; 14: 44-61.
4. Koelewijn JM, de Haas M, Vrijkotte TGM, van der Schoot CE, Bonsel GJ: Risk factors for RhD immunisation despite antenatal and postnatal anti-D prophylaxis. BJOG 2009; 116: 1307-1314.
5. Moise KJJ: Management of rhesus alloimmunization in pregnancy. Obstet Gynecol 2008; 112: 164-176.
6. Crowther C, Middleton P: Anti-D administration after childbirth for preventing Rhesus alloimmunisation. Cochrane Database Syst Rev 2000;2:CD000021.
7. National Institute for Clinical Excellence: Technology appraisal guidance 41. Guidance on the use of routine antenatal anti-D prophylaxis for RhD-negative women. London, NICE, 2002.
8. Foster RP, McIntosh RV, Welch AG: Hepatitis C from anti-D immunoglobulin. Lancet 1995; 346: 372.
9. Lo YMD, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CWG: Presence of fetal DNA in maternal plasma and serum. Lancet 1997; 350: 485-487.
10. Faas BH, Beuling EA, Christiaens GC, dem Borne AE, van der Schoot CE: Detection of fetal RhD-specific sequences in maternal plasma. Lancet 1998; 352: 1196.
11. Geifman-Holtzman O, Grotegut CA, Gaughan JP: Diagnostic accuracy of noninvasive fetal Rh genotyping from maternal blood -a metaanalysis. Am J Obstet Gynecol 2006; 195: 1163-1173.
12. Daniels G, Finning K, Martin P, Massey E: Noninvasive prenatal diagnosis of fetal blood group phenotypes: current practice and future prospects. Prenat Diagn 2009; 29: 101-107.
13. Freeman K, Szczepura A, Osipenko L: Noninvasive fetal RhD genotyping tests: a systemic review of the quality of reporting of diagnostic accuracy in published studies. Eur J Obstet Gynecol Reprod Biol 2009; 142: 91-98.
14. Finning K, Martin P, Summers J, Massey E, Poole G, Daniels G: Effect of high throughput RhD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study. BMJ 2008; 336: 816-818.
15. Muller SP, Bartels I, Stein W, Emons G, Gutensohn K, Kohler M, Legler TJ: The detection of the fetal D status from maternal plasma for decision making on Rh prophylaxis is feasible. Transfusion 2008; 48: 2292-2301.
16. Clausen BF, Christiansen M, Steffensen R, Jorgensen S, Nielsen C, Jakobsen MA, Madsen RD, Jensen K, Krog GR, Rieneck K, Sprogoe U, Homburg KM, Grunnet N, Dziegiel MH: Report of the first nationally implemented clinical routine screening for fetal RhD in RhD negative pregnant women to ascertain the requirement for antenatal RhD prophylaxis. Transfusion 2012; 52: 752-758.
17. Cardo L, Garcia BP, Alvarez FV: Non-invasive fetal RhD genotyping in the first trimester of pregnancy. Clin Chem Lab Med 2010; 48: 1121-1126.
18. Akolekar R, Finning K, Kuppusamy R, Daniels G, Nicolaides KH: Fetal RhD genotyping in maternal plasma at 11-13 weeks of gestation. Fetal Diagn Ther 2011; 29: 301-306.
19. Wikman AT, Tiblad E, Karlsson A, Olsson ML, Westgren M, Reilly M: Noninvasive single- exon fetal RhD determination in a routine screening program in early pregnancy. Obstet Gynecol 2012; 120: 227-234.
20. Daniels G, van der Schoot CE, Olsson ML: Report of the first international workshop on molecular blood group genotyping. Vox Sang 2005; 88: 136-142.
21. Tynan JA, Angkachatchai V, Ehrich M, Paladino T, van den Boom D, Oeth P: Multiplexed analysis of circulating cell-free fetal nucleic acids for noninvasive prenatal diagnostic RhD testing. Am J Obstet Gynecol 2011; 204: 251.e1-251.e6.
22. Bombard AT, Akolekar R, Farkas DH, van Agtmael AL, Aqinu F, Oeth P, Nicolaides KH: Fetal RhD genotype detection from circulating cell-free fetal DNA in maternal plasma in nonsensitized RhD negative women. Prenat Diagn 2011; 31: 802-808.
23. Costa JM, Giovangrandi Y, Ernault P, Lohmann L, Nataf V, El Halali N, Gautier E: Fetal RhD genotyping in maternal serum during the first trimester of pregnancy. Br J Haematol 2002; 119: 255-260.
24. Cardo L, Prieto B, Alvarez FV: Non-invasive fetal RhD genotyping in the first trimester of pregnancy. Clin Chem Lab Med 2010; 48: 1121-1126.
25. Denomme GA, Dake LR, Vilensky D, Ramyar L, Judd WJ: Rh discrepancies caused by variable reactivity of partial and weak D types with different serologic techniques. Transfusion 2008; 48: 473-478.
26. Finning KM, Martin PG, Soothill PW, Avent ND: Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD genotyping service. Transfusion 2002; 42: 1079-1085.
27. van der Schoot CE, Hahn S, Chitty LS: Noninvasive prenatal diagnosis and determination of fetal Rh status. Semin Fetal Neonatal Med 2008; 13: 63-68.
28. Flegel WA, Khull SR, Wagner FF: Primary anti-D immunization by weak D type 2 RBCs. Transfusion 2000; 40: 428-434.
29. Muller SP, Bartels I, Stein W, Emons G, Guthenson K, Legler TJ: Cell-free fetal DNA in specimen from pregnant women is stable up to 5 days. Prenat Diagn 2011; 31: 1300-1304.
30. College National de Gynecolegues et Obstetriciens Francais: Prevention de l'allo-immunisation Rhesus-D foetomaternelle. J Gynecol Obstet Biol Reprod (Paris) 2006; 35: 1S131-1S135.
31. Daniels G, Finning K, Martin P, Soothill P: Fetal blood group genotyping from DNA from maternal plasma: an important advance in the management and prevention of haemolytic disease of the fetus and newborn. Vox Sang 2004; 87: 225-232.
32. Moise KJ: Fetal RhD typing with free DNA in maternal plasma. Am J Obstet Gynecol 2005; 192: 663-665.
33. Franklin IM: Prevention of rhesus haemolytic disease of the fetus and newborn. Lancet 2009; 373: 1082.